Silas Inman

The FDA has accepted an NDA for the oral nucleoside TAS-102 as a treatment for patients with refractory metastatic colorectal cancer.

Cytogenetic and molecular data are becoming increasingly important in the individualization of treatment for patients of acute myeloid leukemia, according to a presentation by Stefan Faderl, MD, at the 2015 International Congress on Hematologic Malignancies.

The FDA has approved panobinostat in combination with bortezomib and dexamethasone for patients with previously treated multiple myeloma, based on findings from the PANORAMA-1 trial.

The FDA has approved its first-ever direct-to-consumer genetic test for the detection of a gene variant that could be associated with Bloom syndrome, a rare inherited disorder associated with a higher risk of developing cancer and other health concerns.

The FDA has scheduled an advisory hearing to discuss the biologics license application for the immunotherapy talimogene laherparepvec as a treatment for patients with metastatic melanoma.

The FDA has granted an accelerated approval to palbociclib as a frontline treatment for postmenopausal women with ER-positive, HER2-negative metastatic breast cancer.

A supplemental New Drug Application has been submitted to the FDA for the full regulatory approval of carfilzomib as a treatment for patients with relapsed multiple myeloma.

ASCO named the vastly improved outlook for patients with chronic lymphocytic leukemia as its inaugural "Cancer Advance of the Year."

Increased utilization of the autologous cellular immunotherapy sipuleucel-T (Provenge) led to a $20.1 million improvement in total revenue in 2014 for the manufacturer Dendreon, when compared with 2013.

Roche has acquired a majority stake in the molecular testing company Foundation Medicine for $1.03 billion, launching a partnership that will focus on the development of personalized medicine for patients with cancer.

The FDA has updated the label for obinutuzumab plus chlorambucil to include data from stage 2 of the phase III CLL11 study, which detailed an unprecedented improvement in progression-free survival compared with rituximab plus chlorambucil as a frontline treatment for patients with chronic lymphocytic leukemia.

The FDA has approved the PD-1 inhibitor nivolumab for patients with unresectable or metastatic melanoma following treatment with ipilimumab or a BRAF inhibitor.

The FDA has approved lanreotide for the treatment of patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors.

Fulvestrant (Faslodex) improved overall survival (OS) by 5.7 months compared with anastrozole as a frontline treatment for postmenopausal women with HR-positive metastatic breast cancer

The addition of bevacizumab (Avastin) to standard neoadjuvant chemotherapy significantly improved pathologic complete response (pCR) rates in women with basal-like breast cancer compared with non-basal-like subtypes.

The PD-1 inhibitor pembrolizumab has demonstrated promising clinical activity with an acceptable safety profile in heavily pretreated patients with recurrent metastatic triple-negative breast cancer.

Patients with HIV-associated lymphoma can effectively be treated with autologous hematopoietic stem cell transplantation, with outcomes that are similar to patients without HIV.

The anti-CD19 chimeric antigen receptor-modified T-cell therapy CTL019 demonstrated an impressive 92% complete response rate in pediatric patients with relapsed/refractory acute lymphoblastic leukemia.

Two studies spotlighted at the 2014 ASH Annual Meeting characterized the efficacy of treatment with anti-CD38 monoclonal antibodies in the frontline setting and for patients with refractory disease.

The FDA has approved the JAK1/2 inhibitor ruxolitinib as treatment for patients with polycythemia vera who are resistant or intolerant to hydroxyurea

The FDA has approved the bispecific T cell engager antibody blinatumomab as a treatment for adult patients with Philadelphia chromosome-negative relapsed/refractory B-precursor acute lymphoblastic leukemia.

The top research being presented at the 2014 American Society of Hematology Annual Meeting will focus on immunotherapies and novel agents, according to Marcel R.M. van den Brink, MD, PhD.

Pfizer and Merck KGaA have agreed to collaborate on the development of the PD-L1 inhibitor MSB0010718C as a potential treatment for multiple types of cancer.

The FDA has extended the review period for panobinostat (LBH589) in combination with bortezomib (Velcade) and dexamethasone for patients with previously treated multiple myeloma by 3 months, placing a new decision date in early 2015.

The chimeric antigen receptor (CAR) T cell therapy JCAR015 has received a breakthrough therapy designation from the FDA as a treatment for patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL).

Treatment with the antibody-drug conjugate T-DM1 (ado-trastuzumab emtansine; Kadcyla) has demonstrated promising clinical efficacy with lower toxicity across a variety of settings for patients with HER2-positive metastatic breast cancer when compared with standard therapies.

The FDA has granted MM-398 (nal-IRI) plus 5-fluorouracil (5-FU) and leucovorin a Fast Track designation as a second-line treatment for patients with metastatic pancreatic cancer

Frontline treatment with nivolumab significantly extended OS and PFS compared with dacarbazine in patients with untreated BRAF wild-type advanced melanoma.

The PD-1 inhibitor pembrolizumab significantly improved PFS by over 43% compared with chemotherapy as a treatment for patients with metastatic melanoma who were refractory to ipilimumab.

The FDA has approved bevacizumab in combination with chemotherapy for patients with recurrent platinum-resistant ovarian cancer.